Abivax SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0012333284
EUR
108.20
-7.6 (-6.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

How big is Abivax SA?

22-Jun-2025

As of Jun 19, Abivax SA has a market capitalization of 340.65 million, classifying it as a Micro Cap company. There is no valid financial data available for net sales or net profit for the latest four quarters.

Market Cap: As of Jun 19, Abivax SA has a market capitalization of 340.65 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: As of December 2024, the shareholder's funds are reported at 40.58 million, and total assets amount to 205.23 million.

Read More

What does Abivax SA do?

22-Jun-2025

Abivax SA is a clinical stage biopharmaceutical company focused on developing novel anti-viral compounds and therapeutic vaccines for severe infectious diseases, with a market cap of EUR 340.65 million. It currently has no earnings or dividends and significant negative return on equity.

Overview:<BR>Abivax SA is a clinical stage biopharmaceutical company in the Pharmaceuticals & Biotechnology industry, focusing on the discovery, development, and commercialization of novel anti-viral compounds and therapeutic vaccines against severe infectious diseases.<BR><BR>Financial Snapshot:<BR>Market cap: EUR 340.65 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.22<BR>Return on Equity: -432.23%<BR>Price to Book: 8.39<BR><BR>Contact Details:<BR>Address: 5, rue de la Baume, Paris 8, PARIS None: 75008<BR>Tel: ['33 1 53830841']<BR>Fax: 33 4 94279261<BR>Website: http://www.abivax.com/

Read More

Who are in the management team of Abivax SA?

22-Jun-2025

As of March 2022, the management team of Abivax SA includes Dr. Philippe Pouletty (Chairman), Ms. Joy Amundson, Dr. Claude Bertrand, Mr. Jean-Jacques Bertrand, Mr. Jerome Gallot, and Mr. Antoine Pau, who oversee the company's strategic direction and governance.

As of March 2022, the management team of Abivax SA includes the following individuals:<BR><BR>- Dr. Philippe Pouletty, Chairman of the Board<BR>- Ms. Joy Amundson, Director<BR>- Dr. Claude Bertrand, Director<BR>- Mr. Jean-Jacques Bertrand, Director<BR>- Mr. Jerome Gallot, Director<BR>- M. Antoine Pau, Director<BR><BR>This team is responsible for overseeing the strategic direction and governance of the company.

Read More

Is Abivax SA technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, Abivax SA exhibits a bearish technical stance overall, with mixed signals from indicators like the MACD and Bollinger Bands suggesting weak upward momentum.

As of 1 October 2023, the technical stance for Abivax SA is bearish with mild strength. The weekly MACD indicates a mildly bullish trend, but the monthly MACD is bearish, suggesting a lack of strong upward momentum. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages also reflect a bearish sentiment. The Dow Theory shows a mildly bearish stance on both weekly and monthly charts. Although the KST is mildly bullish weekly, the overall indicators point to a bearish trend, particularly in the longer time frames.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Dec 24

  • OPERATING CASH FLOW(Y) Lowest at EUR -253.6 MM
  • OPERATING PROFIT(Q) Lowest at EUR -98.1 MM
2

Risky -

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 7,907 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.22

stock-summary
Return on Equity

363.33%

stock-summary
Price to Book

-163.78

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
53.04%
0%
53.04%
6 Months
1631.2%
0%
1631.2%
1 Year
1354.3%
0%
1354.3%
2 Years
1038.95%
0%
1038.95%
3 Years
1679.61%
0%
1679.61%
4 Years
331.08%
0%
331.08%
5 Years
395.19%
0%
395.19%

Abivax SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-221.82%
EBIT to Interest (avg)
-13.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.22
Sales to Capital Employed (avg)
0
Tax Ratio
3.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.94%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-100.17
EV to EBIT
-26.20
EV to EBITDA
-26.36
EV to Capital Employed
-189.80
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Abivax SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -19.30% vs -143.33% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-184.30",
          "val2": "-131.30",
          "chgp": "-40.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "14.10",
          "val2": "15.80",
          "chgp": "-10.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.80",
          "val2": "-1.90",
          "chgp": "57.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-176.20",
          "val2": "-147.70",
          "chgp": "-19.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-184.30
-131.30
-40.37%
Interest
14.10
15.80
-10.76%
Exceptional Items
-0.80
-1.90
57.89%
Consolidate Net Profit
-176.20
-147.70
-19.30%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -19.30% vs -143.33% in Dec 2023

stock-summaryCompany CV
About Abivax SA stock-summary
stock-summary
Abivax SA
Pharmaceuticals & Biotechnology
ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Coordinates stock-summary
Company Details
5, rue de la Baume, Paris 8 , PARIS None : 75008
stock-summary
Tel: 33 1 53830841
stock-summary
Registrar Details